Related Experiment Video

Updated: Jul 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

[Novel inhibitors of Bcr-Abl]

Justyna Jakubowska1, Małgorzata Czyz

  • 1Zakład Biologii Molekularnej Nowotworów Uniwersytetu Medycznego w Łodzi.

Postepy Higieny I Medycyny Doswiadczalnej (Online)
|January 25, 2007
PubMed

Insights

Second-generation tyrosine kinase inhibitors offer new hope for chronic myeloid leukemia (CML) patients resistant to imatinib (STI571). This review explores alternative drugs designed to overcome resistance and target Bcr-Abl protein more effectively.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Imatinib (STI571) is a targeted therapy for Philadelphia chromosome-positive chronic myeloid leukemia (CML).
  • While effective in the chronic phase, imatinib resistance often develops in accelerated or blast crisis phases.
  • Leukemic stem cells and BCR-ABL positive cells persist despite imatinib treatment.

Purpose of the Study:

  • To review alternative tyrosine kinase inhibitors developed to overcome imatinib resistance in CML.
  • To present an overview of newer drugs designed for higher efficiency against Bcr-Abl protein.

Main Methods:

  • Literature review of alternative targeted therapies for CML.
  • Analysis of inhibitors designed to bypass imatinib resistance mechanisms.

Main Results:

  • Development of second-generation tyrosine kinase inhibitors.
  • These inhibitors aim to more effectively target Bcr-Abl kinase activity.

Conclusions:

  • Alternative inhibitors are crucial for managing imatinib-resistant CML.
  • Newer targeted therapies offer improved efficacy for advanced CML phases.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...